Skip to content
2023 is shaping up to be the year of RSV—in a good way. RSV (a.k.a. respiratory syncytial virus) has long been a challenge for […]
Pediatrics might finally have a long-awaited RSV shot Read More »
Already, 2023 is looking like a dynamic year for biotech on the state level as state legislatures nationwide get ready to tackle a few
4 things for biotech to watch in the 2023 state legislatures Read More »
The number of new pain drugs in the development pipeline has slowed to a trickle and investment in addiction drugs is low, challenges addressed
‘All hands on deck’ needed to address U.S. pain and addiction innovation Read More »
“I think we’re in a very exciting time in healthcare and biotech,” said Steven Ladd, Director of Business Development and Acquisitions at AbbVie. “It’s
China-U.S. biotech ventures are where collaboration meets competition Read More »
“It’s exciting times,” said Kathy Fernando, Senior Vice President and Global Head of the Partner of Choice Organization at Pfizer Inc. Speaking about the
Pfizer Ignite’s new model is turning heads and sharing the wealth Read More »
From the colorful glass and plastic bottles that populate medicine cabinets to the ingredients used in common and high-end products, the beauty industry’s output
Biotech can clean up your beauty cabinet for the new year Read More »
At 30-years old, the 340B program is buckling under its own weight and overdue for reform. With legal action, including a Supreme Court ruling,
The 30-year-old 340B drug discount program is due for reform Read More »
It’s no surprise the COVID-19 pandemic aggravated the United States’ already rampant opioid epidemic. But what’s more surprising, and devastating, has been the increase
Teen opioid deaths are on the rise – but OTC Narcan could help Read More »
Could the Office of the U.S. Trade Representative’s (USTR) position on the COVID IP waiver be shifting? On December 6, USTR announced support for “extending
U.S. punts decision on COVID IP waiver to 2023 Read More »
Dobbs v. Jackson has had a ripple effect across healthcare—from increasing the danger of medical management of miscarriages and risk of maternal mortality, to
How Dobbs v. Jackson is affecting vaccine innovation Read More »
